

Clinical trials of angiogenesis inhibitors for renal-cell carcinoma (advanced) in all type of patients

TrialResults-center www.trialresultscenter.org

1 bevacizumab

Trial	Treatments	Patients	Trials design and methods
bevacizumab plus interferon alfa vs interferon alpha			
CALGB 90206 , 2010 n=369/363 follow-up:	bevacizumab (10 mg/kg intravenously every 2 weeks) plus IFN- (9 million units subcutaneously three times weekly) versus same dose and schedule of IFN- monotherapy	Patients with previously untreated, metastatic clear cell RCC	Parallel groups
AVOREN , 2007 n=327/322 follow-up:	bevacizumab (10 mg/kg every 2 weeks) plus IFN (9 MIU subcutaneously three times a week) versus IFN plus placebo	patients with previously untreated mRCC	
bevacizumab vs placebo			
Yang , 2003 n=76/40 follow-up:	bevacizumab at doses of 3 and 10 mg per kilogram of body weight, given every two weeks versus placebo	patients with metastatic renal-cell carcinoma	Parallel groups

References

CALGB 90206, 2010:

Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ, Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. *J Clin Oncol* 2010;28:2137-43. [[20368558](#)] [10.1200/JCO.2009.26.5561](https://doi.org/10.1200/JCO.2009.26.5561)

Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ, Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. *J Clin Oncol* 2008;26:5422-8. [[18936475](#)] [10.1200/JCO.2008.16.9847](https://doi.org/10.1200/JCO.2008.16.9847)

Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL, , Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. *Clin Cancer Res* 2004;10:2584-6. [[15102658](#)]

AVOREN, 2007:

Escudier B, Bellmunt J, Ngrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V, Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. *J Clin Oncol* 2010;28:2144-50. [[20368553](#)] [10.1200/JCO.2009.26.7849](https://doi.org/10.1200/JCO.2009.26.7849)

Melichar B, Koralewski P, Ravaud A, Pluzanska A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Delva R, Sevin E, Ngrier S, McKendrick J, Santoro A, Pisa P, Escudier B, First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. *Ann Oncol* 2008;19:1470-6. [[18408224](#)] [10.1093/annonc/mdn161](https://doi.org/10.1093/annonc/mdn161)

Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. *Lancet* 2007;370:2103-11 [[18156031](#)]

Yang, 2003:

Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34. [[12890841](#)] [10.1056/NEJMoa021491](#)

Yang JC Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res 2004;10:6367S-70S [[15448032](#)]

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.